Skip to main content

Table 2 Treatment outcomes in afatinib and erlotinib arm

From: Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

 

Afatinib (%)

Erlotinib (%)

p-value

Best response

  

0.09

  CR

0 (0.0)

0 (0.0)

 

  PR

5 (20.0)

2 (7.1)

 

  SD

12 (48.0)

9 (32.1)

 

  PD

8 (32.0)

17 (60.7)

 

Objective response rate

5 (20.0)

2 (7.1)

0.17

Disease control rate

17 (68.0)

11 (39.3)

0.04

Objective response of brain metastases

3 (12.0)

4 (14.3)

0.81

Median duration of treatment (months, range)

4.5 (0.2–22.7)

3.3 (0.3–48.7)

0.52

Median time to progression (months, range)

3.3 (0.2–12.6)

3.3 (0.3–14.4)

0.77

Median PFS (95 % CI) (months)

4.1 (2.7–5.5)

3.3 (2.2–4.4)

0.97

Median OS (95 % CI) (months)

10.3 (7.5–13.0)

10.8 (7.4–14.2)

0.51

  1. Abbreviations: CI confidence interval, CR complete response, PD progressive disease, PFS progression-free survival, PR partial response, SD stable disease, TKI tyrosine-kinase inhibitor